单克隆抗体药物治疗多发性硬化症和视神经脊髓炎谱系障碍

Q4 Immunology and Microbiology

Clinical and Experimental Neuroimmunology Pub Date : 2022-07-25 DOI:10.1111/cen3.12725

Hisashi Murata, Yasuko Sugiyama, Naoyuki Shiraishi, Keigo Kihara, Makoto Kinoshita, Tatsusada Okuno

{"title":"单克隆抗体药物治疗多发性硬化症和视神经脊髓炎谱系障碍","authors":"Hisashi Murata, Yasuko Sugiyama, Naoyuki Shiraishi, Keigo Kihara, Makoto Kinoshita, Tatsusada Okuno","doi":"10.1111/cen3.12725","DOIUrl":null,"url":null,"abstract":"<p>In recent years, remarkable advances have been made in the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). In particular, several monoclonal antibody drugs have been approved for the treatment of MS and NMOSD, significantly expanding the therapeutic options for treating these diseases. This article provides an overview of the monoclonal antibodies available to treat patients with MS and NMOSD, including drugs that are not yet approved in Japan.</p>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Monoclonal antibody drugs for the treatment of multiple sclerosis and neuromyelitis optica spectrum disorder\",\"authors\":\"Hisashi Murata, Yasuko Sugiyama, Naoyuki Shiraishi, Keigo Kihara, Makoto Kinoshita, Tatsusada Okuno\",\"doi\":\"10.1111/cen3.12725\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In recent years, remarkable advances have been made in the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). In particular, several monoclonal antibody drugs have been approved for the treatment of MS and NMOSD, significantly expanding the therapeutic options for treating these diseases. This article provides an overview of the monoclonal antibodies available to treat patients with MS and NMOSD, including drugs that are not yet approved in Japan.</p>\",\"PeriodicalId\":10193,\"journal\":{\"name\":\"Clinical and Experimental Neuroimmunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Neuroimmunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cen3.12725\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Neuroimmunology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen3.12725","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 0

摘要

近年来，在治疗多发性硬化症（MS）和视神经脊髓炎谱系障碍（NMOSD）方面取得了显著进展。特别是，几种单克隆抗体药物已被批准用于治疗多发性硬化症和NMOSD，大大扩大了治疗这些疾病的治疗选择。本文概述了可用于治疗MS和NMOSD患者的单克隆抗体，包括尚未在日本批准的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Monoclonal antibody drugs for the treatment of multiple sclerosis and neuromyelitis optica spectrum disorder

In recent years, remarkable advances have been made in the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). In particular, several monoclonal antibody drugs have been approved for the treatment of MS and NMOSD, significantly expanding the therapeutic options for treating these diseases. This article provides an overview of the monoclonal antibodies available to treat patients with MS and NMOSD, including drugs that are not yet approved in Japan.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical and Experimental Neuroimmunology Immunology and Microbiology-Immunology and Microbiology (miscellaneous)

CiteScore

1.60

自引率

0.00%

发文量